Literature DB >> 8551600

Human immunodeficiency virus type 1 tropism for T-lymphoid cell lines: role of the V3 loop and C4 envelope determinants.

A Carrillo1, L Ratner.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8551600      PMCID: PMC189948     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


× No keyword cloud information.
  85 in total

1.  Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes.

Authors:  P Westervelt; H E Gendelman; L Ratner
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 2.  Neutralization of HIV-1: a paradox of humoral proportions.

Authors:  P L Nara; R R Garrity; J Goudsmit
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

3.  Soluble CD4 and dextran sulfate mediate release of gp120 from HIV-1: implications for clinical trials.

Authors:  P J Bugelski; H Ellens; T K Hart; R L Kirsh
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1991

4.  The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?

Authors:  G J Clements; M J Price-Jones; P E Stephens; C Sutton; T F Schulz; P R Clapham; J A McKeating; M O McClure; S Thomson; M Marsh
Journal:  AIDS Res Hum Retroviruses       Date:  1991-01       Impact factor: 2.205

5.  Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual.

Authors:  M Groenink; R A Fouchier; R E de Goede; F de Wolf; R A Gruters; H T Cuypers; H G Huisman; M Tersmette
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

6.  Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

Authors:  T K Hart; R Kirsh; H Ellens; R W Sweet; D M Lambert; S R Petteway; J Leary; P J Bugelski
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

7.  Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein.

Authors:  E Helseth; U Olshevsky; C Furman; J Sodroski
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

8.  Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1.

Authors:  S S Hwang; T J Boyle; H K Lyerly; B R Cullen
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

9.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes.

Authors:  Y Li; J C Kappes; J A Conway; R W Price; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

10.  Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding.

Authors:  Q J Sattentau; J P Moore
Journal:  J Exp Med       Date:  1991-08-01       Impact factor: 14.307

View more
  40 in total

1.  Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopes.

Authors:  Y Yamaguchi-Kabata; T Gojobori
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Distinct human immunodeficiency virus strains in the bone marrow are associated with the development of thrombocytopenia.

Authors:  F Voulgaropoulou; B Tan; M Soares; B Hahn; L Ratner
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

3.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Authors:  Mia Coetzer; Rebecca Nedellec; Tonie Cilliers; Tammy Meyers; Lynn Morris; Donald E Mosier
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

5.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Evolutionary variants of the human immunodeficiency virus type 1 V3 region characterized by using a heteroduplex tracking assay.

Authors:  J A Nelson; S A Fiscus; R Swanstrom
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

8.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

9.  Impact of mutations outside the V3 region on coreceptor tropism phenotypically assessed in patients infected with HIV-1 subtype B.

Authors:  Laura Monno; Annalisa Saracino; Luigia Scudeller; Grazia Punzi; Gaetano Brindicci; Maurantonio Altamura; Antonella Lagioia; Nicoletta Ladisa; Gioacchino Angarano
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

10.  Evolution of HIV-1 coreceptor usage and coreceptor switching during pregnancy.

Authors:  Doris G Ransy; Alena Motorina; Natacha Merindol; Bertine S Akouamba; Johanne Samson; Yolanda Lie; Laura A Napolitano; Normand Lapointe; Marc Boucher; Hugo Soudeyns
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-25       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.